Chimpanzee adenovirus encoding sars-cov-2 spike glycoprotein
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
2021
- First approval year
- 2021
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Chimpanzee adenovirus encoding sars-cov-2 spike glycoprotein
- Vaxzevria (previously covid-19 vaccine astrazeneca)
- vaxzevria previously covid 19 vaccine astrazeneca
- chimpanzee adenovirus encoding sars cov 2 spike glycoprotein
- Chimpanzee adenovirus encoding sars-cov-2 spike glycoprotein
- vaxzevria
- Vaxzevria
- Vaxzevria®
- ChEMBL ID
- CHEMBL6068380
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -vir-
Mechanisms of action
- Mechanism
- Spike glycoprotein vaccine antigen
- Action type
- VACCINE_ANTIGEN
- Target
- Spike glycoprotein
- Protein identifier
- P0DTC2
Open Targets mechanisms
- Mechanism
- Spike glycoprotein vaccine antigen
- Action type
- VACCINE ANTIGEN
- Target
- Spike glycoprotein
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition
- COVID-19
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0100096
- Subject identifier
- D000086382
- Condition identifier
- MONDO_0100096
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (4)
- Booster Superiority Study of PTX-COVID19-B Compared to Vaxzevria® in Adults Aged 18 Years and Older
- Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2
- Immunogenicity and Safety Study of SCB-2019 Vaccine as a Booster to COVID-19 Vaccine in Adults
- Prospective Monitoring of Antibody Response Following COVID-19 Vaccination in Patients With Down Syndrome.